"We are thrilled to partner with Hikma, a company with a strong presence in the MENA region and a proven track record of successful collaborations," said Michael Na, CEO of CanariaBio.

Oregovomab is being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer in the phase 3 FLORA-5 trial. In Phase 2, the addition of oregovomab yielded a median progression-free survival of 41.8 months compared with 12.2 months with standard chemotherapy (HR, 0.46, P=0.0027). The hazard ratio of overall survival was 0.35.

Oregovomab is a murine monoclonal antibody direct to the tumor-associated antigen CA125 that stimulates a host cytotoxic immune response against tumor cells expressing CA 125, a biomarker commonly found in ovarian cancer (OC). In a randomized Phase II clinical trial, oregovomab demonstrated a significant improvement in progression-free and overall survival in advanced OC treatment when administered simultaneously with first-line chemotherapy. This promising schedule is currently investigated in a phase III trial.